Consensus Sutro Biopharma, Inc.

Stocks

STRO

US8693672011

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:56:23 2026-10-28 EDT			5-day change	1st Jan Change
8.920 ^USD	+0.56%		-18.26%	-23.77%

10-21	Sutro Biopharma, Inc. Announces First Patient Dosed In Phase 1 Trial Of STRO-006 In Advanced Solid Tumors	CI
09-29	Sutro Biopharma, Inc. Announces Appointment of Lucas Donigian as Senior Vice President, Business Development, Effective September 28, 2026	CI

Evolution of the Average Target: Sutro Biopharma, Inc.

Evolution of the Target Price: Sutro Biopharma, Inc.

Changes in Analyst Recommendations: Sutro Biopharma, Inc.

6f7113ac76b8cb.rWrgQDEBtluRyCkBrFgigmSreDqs2bjV8FvsX5YnroQ.zhi1CFdx5BGlhnk22TAU0yn4N03zrsrluw61GPFs4t3yIc11RVOBCqPwQg~ccb3854bc0454279dea63145958a9b13

Analysts' recommendations: Sutro Biopharma, Inc.

05-28	Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target	MT
05-15	Sutro Biopharma Shares Rise After Q1 Loss Narrows	MT
05-15	Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22	MT
04-30	Mizuho Initiates Sutro Biopharma at Outperform With $50 Price Target	MT
04-07	Leerink Partners Initiates Sutro Biopharma at Outperform With $38 Price Target	MT
03-25	Deutsche Bank Adjusts Sutro Biopharma Price Target to $55 From $51, Maintains Buy Rating	MT
03-24	Wells Fargo Upgrades Sutro Biopharma to Overweight From Equal Weight, Adjusts PT to $27 From $8	MT
03-24	HC Wainwright Upgrades Sutro Biopharma to Buy From Neutral, Adjusts PT to $28 From $10	MT
03-24	Wedbush Raises Price Target on Sutro Biopharma to $22 From $10, Keeps Neutral Rating	MT
12-17	Deutsche Bank Boosts Price Target on Sutro Biopharma to $51 From $5, Keeps Buy Rating	MT
25-06-16	Piper Sandler Upgrades Sutro Biopharma to Overweight From Neutral, $2 Price Target	MT
25-03-17	HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2	MT
25-03-17	Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform	MT
25-03-17	Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating	MT
25-03-14	Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8	MT
25-03-14	Wedbush Downgrades Sutro Biopharma to Neutral From Outperform, Adjusts Price Target to $2 From $8	MT
25-03-14	Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating	MT
24-08-16	Truist Securities Adjusts Price Target on Sutro Biopharma to $15 From $18, Maintains Buy Rating	MT
24-05-08	BofA Securities Starts Sutro Biopharma With Buy Rating	MT
24-04-03	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT
24-04-03	Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	MT
24-03-26	Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	MT
23-11-15	Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	MT
23-10-06	Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	MT
23-08-11	Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SUTRO BIOPHARMA, INC.					+432.48%
	WUXI APPTEC CO., LTD.					+41.32%
	ARGENX SE					+28.63%
	LONZA GROUP AG					+9.56%
	IQVIA HOLDINGS INC.					+12.15%
	BEONE MEDICINES AG					+19.23%
	REVOLUTION MEDICINES, INC.					+39%
	CELLTRION, INC.					+42.31%
	GENMAB A/S					+6.5%
	WUXI BIOLOGICS (CAYMAN) INC.					+35.02%
	Average					+66.62%
	Weighted average by Cap.					+26.35%